- Home
- BKYI vs CNSP Comparison
BKYI vs CNSP Comparison
Compare BKYI & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- CNSP
- Stock Information
- Founded
- BKYI 1993
- CNSP 2017
- Country
- BKYI United States
- CNSP United States
- Employees
- BKYI N/A
- CNSP N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- BKYI Technology
- CNSP Health Care
- Exchange
- BKYI Nasdaq
- CNSP Nasdaq
- Market Cap
- BKYI 4.8M
- CNSP 4.0M
- IPO Year
- BKYI 1997
- CNSP 2019
- Fundamental
- Price
- BKYI $0.75
- CNSP $6.25
- Analyst Decision
- BKYI
- CNSP Hold
- Analyst Count
- BKYI 0
- CNSP 1
- Target Price
- BKYI N/A
- CNSP N/A
- AVG Volume (30 Days)
- BKYI 141.0K
- CNSP 80.6K
- Earning Date
- BKYI 08-13-2025
- CNSP 08-14-2025
- Dividend Yield
- BKYI N/A
- CNSP N/A
- EPS Growth
- BKYI N/A
- CNSP N/A
- EPS
- BKYI N/A
- CNSP N/A
- Revenue
- BKYI $6,911,148.00
- CNSP N/A
- Revenue This Year
- BKYI $7.45
- CNSP N/A
- Revenue Next Year
- BKYI $23.29
- CNSP N/A
- P/E Ratio
- BKYI N/A
- CNSP N/A
- Revenue Growth
- BKYI N/A
- CNSP N/A
- 52 Week Low
- BKYI $0.52
- CNSP $4.93
- 52 Week High
- BKYI $3.68
- CNSP $221.94
- Technical
- Relative Strength Index (RSI)
- BKYI 44.74
- CNSP 42.15
- Support Level
- BKYI $0.71
- CNSP $5.85
- Resistance Level
- BKYI $0.84
- CNSP $6.70
- Average True Range (ATR)
- BKYI 0.04
- CNSP 0.95
- MACD
- BKYI 0.00
- CNSP 0.14
- Stochastic Oscillator
- BKYI 30.77
- CNSP 45.12
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.